A judge has refused a bid by Macquarie Bank and a group of former financial advisers to preside over a mediation of their spat over $2.6 million in wages, saying a judge can’t act as a mediator and he wouldn’t do it even if he could.
The Commonwealth Bank of Australia has offered $9.3 million since 2014 to customers that suffered loss when advisers in two of its financial planning units put their money into high-risk investments without their permission.
By putting its name on allegedly defective vaginal mesh implants, American Medical Systems held itself out as the manufacture of those devices, according to an amended class action pleading that addresses the medical device maker’s assertion that a subsidiary made the devices after May 2012.
US lingerie company Victoria’s Secret has reached a settlement in a lawsuit over the sale of knockoff products that mimic the get-up of its trade marked body care products.
F. Hoffman La-Roche has reached a settlement in a patent lawsuit over Sandoz’s plan to market a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
The takeover battle for Xenith IP has entered round two, with IPH submitting a revised proposal to acquire the IP services firm in full, leaving fellow suitor QANTM with three days to lodge a competing offer.
Funding for a shareholder class action against mineral sands company Iluka Resources is in doubt after Harbour Litigation Funding unilaterally backed out of an agreement to finance the litigation.
NewLaw pioneer and founder of Bespoke Law, Jeremy Szwider, has been found guilty of professional misconduct and unsatisfactory professional conduct after taking on a case he was “uniquely unprepared” to handle.
A judge has rejected a bid by former directors of Slater & Gordon to throw out cross claims brought by Pitcher Partners in two shareholder class actions alleging the accounting firm wrongly signed off on the law firm’s financial reports ahead of a share price nosedive, saying it was possible Pitcher Partners’ claimed reliance on representations by the directors was reasonable.
Global pharmaceutical giant Lundbeck has launched a bid to escape a prior undertaking blocking it from appealing a court’s decision that allowed four generic drug makers to apply for licences to manufacture generic versions of popular antidepressant Lexapro.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
